Loading…

A LARGE QUANTITY OF CD3− CD19− CD16− LYMPHOCYTES IN MALIGNANT PLEURAL EFFUSION FROM A PATIENT WITH RECURRENT CHOLANGIO CELL CARCINOMA

Tumor infiltrating lymphocytes (TILs) are candidates for adoptive cellular immunotherapy. Here we report on a patient whose TILs presented unusual lymphocyte antigens. Pleural effusions were collected from a 47-year-old man with recurrent cholangio cell carcinoma and malignant effusion. Effusion- as...

Full description

Saved in:
Bibliographic Details
Published in:Immunological investigations 2002-01, Vol.31 (2), p.121-135
Main Authors: Onishi, Hideya, Morisaki, Takashi, Kuga, Hirotaka, Katano, Mitsuo, Doi, Fukashi, Uchiyama, Akihiko, Sugitani, Atsushi, Wada, Junji, Chijiiwa, Kazuo, Tanaka, Masao
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c386t-1d3c84bfee1d05d02283f23a271f0c917af40280f19dd3d1d1a674479ee72d2a3
cites cdi_FETCH-LOGICAL-c386t-1d3c84bfee1d05d02283f23a271f0c917af40280f19dd3d1d1a674479ee72d2a3
container_end_page 135
container_issue 2
container_start_page 121
container_title Immunological investigations
container_volume 31
creator Onishi, Hideya
Morisaki, Takashi
Kuga, Hirotaka
Katano, Mitsuo
Doi, Fukashi
Uchiyama, Akihiko
Sugitani, Atsushi
Wada, Junji
Chijiiwa, Kazuo
Tanaka, Masao
description Tumor infiltrating lymphocytes (TILs) are candidates for adoptive cellular immunotherapy. Here we report on a patient whose TILs presented unusual lymphocyte antigens. Pleural effusions were collected from a 47-year-old man with recurrent cholangio cell carcinoma and malignant effusion. Effusion- associated lymphocytes (EALs) were separated by Ficoll-Hypaque gradient, and the EAL phenotype was determined by flow cytometry. The percentage of positive cells was determined for each lymphocyte-related differentiation antigen. The percentages of CD3+, CD19+, and CD16+ lymphocyte subpopulations among EALs were 20%, 7%, and 3%, respectively. Nearly 70% of EALs were CD3− CD19− CD56− CD16−cells. The phenotypes of peripheral blood lymphocytes (PBLs) collected simultaneously from the patient's peripheral blood were CD3+ (52%), CD19+ (20%), and CD16+ (20%).When EALs were cultured in medium without pleural effusion, T cell-related antigens, but not B cell- or natural killer (NK) cell-related antigens, were newly expressed on EALs, and this expression reached a plateau after 48 h in culture. The proportions of CD3+, CD19+, and CD16+ cells were 69%, 7%, and 3%, respectively. However, when EALs were cultured in medium with pleural effusion, increased expression of T cell-related antigens was not observed; the proportions of CD3+, CD19+, and CD16+ cells were 16%, 6%, and 1%, respectively. Neither total cell numbers nor cellular viability of EALs changed significantly after in-vitro culture, suggesting that significant proliferation or death of EALs did not occur during the culture period. Co-culture of the patient's PBLs with autologous pleural effusion for 96 h did not alter the expression of lymphocyte-related antigens on the PBLs. These results indicate that expression of T cell-related antigens, but not B cell- or NK cell-related antigens, on EALs was blocked temporarily by the malignant pleural effusion. This is the first report concerning the existence of a large quantity of unclassified lymphocytes in which the T cell-related antigens were reversibly masked in the malignant pleural effusion.
doi_str_mv 10.1081/IMM-120004803
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_12148948</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71955780</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-1d3c84bfee1d05d02283f23a271f0c917af40280f19dd3d1d1a674479ee72d2a3</originalsourceid><addsrcrecordid>eNp1kMGK2zAQhkVp6aZpj70WnXpzq5HsWD4K104Esp16bUpORmvJbBYn3pUTyr5Bobc-4j7JOiS09LCnn2G--Rk-hD4C-QKEw1eZZR5QQojPCXuFZhAw6vkM4DWaEc6pR4BFV-jdON5NEAsW0Vt0BRR8Hvl8hn4LrES5TPD3WuSVrDa4SHH8jT39-jMFRJdcnFJtsvWqiDdVco1ljjOh5DKfrvBaJXUpFE7StL6WRY7TssiwwGtRyWTa_5DVCpdJXJflaYxXhRL5UhY4TpTCsShjmReZeI_edLof7YdLzlGdJlW88lSxlLFQXsv44uCBYS33bzprwZDAEEo56yjTNISOtBGEuvMJ5aSDyBhmwIBehL4fRtaG1FDN5ujzuffeDQ9HOx6a3XZsbd_rvR2OYxNCFAThpHOOvDPYumEcne2ae7fdaffYAGlO9pvJfvPX_sR_uhQfb3bW_KMvuieAn4HtvhvcTv8cXG-ag37sB9c5vW-3Y8Ne6g7_O721uj_cttrZ5m44uv0k7IWvngGZIpsm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71955780</pqid></control><display><type>article</type><title>A LARGE QUANTITY OF CD3− CD19− CD16− LYMPHOCYTES IN MALIGNANT PLEURAL EFFUSION FROM A PATIENT WITH RECURRENT CHOLANGIO CELL CARCINOMA</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Onishi, Hideya ; Morisaki, Takashi ; Kuga, Hirotaka ; Katano, Mitsuo ; Doi, Fukashi ; Uchiyama, Akihiko ; Sugitani, Atsushi ; Wada, Junji ; Chijiiwa, Kazuo ; Tanaka, Masao</creator><creatorcontrib>Onishi, Hideya ; Morisaki, Takashi ; Kuga, Hirotaka ; Katano, Mitsuo ; Doi, Fukashi ; Uchiyama, Akihiko ; Sugitani, Atsushi ; Wada, Junji ; Chijiiwa, Kazuo ; Tanaka, Masao</creatorcontrib><description>Tumor infiltrating lymphocytes (TILs) are candidates for adoptive cellular immunotherapy. Here we report on a patient whose TILs presented unusual lymphocyte antigens. Pleural effusions were collected from a 47-year-old man with recurrent cholangio cell carcinoma and malignant effusion. Effusion- associated lymphocytes (EALs) were separated by Ficoll-Hypaque gradient, and the EAL phenotype was determined by flow cytometry. The percentage of positive cells was determined for each lymphocyte-related differentiation antigen. The percentages of CD3+, CD19+, and CD16+ lymphocyte subpopulations among EALs were 20%, 7%, and 3%, respectively. Nearly 70% of EALs were CD3− CD19− CD56− CD16−cells. The phenotypes of peripheral blood lymphocytes (PBLs) collected simultaneously from the patient's peripheral blood were CD3+ (52%), CD19+ (20%), and CD16+ (20%).When EALs were cultured in medium without pleural effusion, T cell-related antigens, but not B cell- or natural killer (NK) cell-related antigens, were newly expressed on EALs, and this expression reached a plateau after 48 h in culture. The proportions of CD3+, CD19+, and CD16+ cells were 69%, 7%, and 3%, respectively. However, when EALs were cultured in medium with pleural effusion, increased expression of T cell-related antigens was not observed; the proportions of CD3+, CD19+, and CD16+ cells were 16%, 6%, and 1%, respectively. Neither total cell numbers nor cellular viability of EALs changed significantly after in-vitro culture, suggesting that significant proliferation or death of EALs did not occur during the culture period. Co-culture of the patient's PBLs with autologous pleural effusion for 96 h did not alter the expression of lymphocyte-related antigens on the PBLs. These results indicate that expression of T cell-related antigens, but not B cell- or NK cell-related antigens, on EALs was blocked temporarily by the malignant pleural effusion. This is the first report concerning the existence of a large quantity of unclassified lymphocytes in which the T cell-related antigens were reversibly masked in the malignant pleural effusion.</description><identifier>ISSN: 0882-0139</identifier><identifier>EISSN: 1532-4311</identifier><identifier>DOI: 10.1081/IMM-120004803</identifier><identifier>PMID: 12148948</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Antigens, CD19 - metabolism ; CD3 Complex - metabolism ; Cholangiocarcinoma - immunology ; Cholangiocarcinoma - therapy ; Humans ; Immunotherapy, Adoptive ; In Vitro Techniques ; Interferon-gamma - biosynthesis ; Lymphocytes, Tumor-Infiltrating - immunology ; Male ; Middle Aged ; Neoplasm Recurrence, Local - immunology ; Neoplasm Recurrence, Local - therapy ; Picibanil - pharmacology ; Pleural Effusion, Malignant - immunology ; Pleural Effusion, Malignant - therapy ; Receptors, IgG - metabolism ; T-Lymphocytes - immunology</subject><ispartof>Immunological investigations, 2002-01, Vol.31 (2), p.121-135</ispartof><rights>2002 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-1d3c84bfee1d05d02283f23a271f0c917af40280f19dd3d1d1a674479ee72d2a3</citedby><cites>FETCH-LOGICAL-c386t-1d3c84bfee1d05d02283f23a271f0c917af40280f19dd3d1d1a674479ee72d2a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12148948$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Onishi, Hideya</creatorcontrib><creatorcontrib>Morisaki, Takashi</creatorcontrib><creatorcontrib>Kuga, Hirotaka</creatorcontrib><creatorcontrib>Katano, Mitsuo</creatorcontrib><creatorcontrib>Doi, Fukashi</creatorcontrib><creatorcontrib>Uchiyama, Akihiko</creatorcontrib><creatorcontrib>Sugitani, Atsushi</creatorcontrib><creatorcontrib>Wada, Junji</creatorcontrib><creatorcontrib>Chijiiwa, Kazuo</creatorcontrib><creatorcontrib>Tanaka, Masao</creatorcontrib><title>A LARGE QUANTITY OF CD3− CD19− CD16− LYMPHOCYTES IN MALIGNANT PLEURAL EFFUSION FROM A PATIENT WITH RECURRENT CHOLANGIO CELL CARCINOMA</title><title>Immunological investigations</title><addtitle>Immunol Invest</addtitle><description>Tumor infiltrating lymphocytes (TILs) are candidates for adoptive cellular immunotherapy. Here we report on a patient whose TILs presented unusual lymphocyte antigens. Pleural effusions were collected from a 47-year-old man with recurrent cholangio cell carcinoma and malignant effusion. Effusion- associated lymphocytes (EALs) were separated by Ficoll-Hypaque gradient, and the EAL phenotype was determined by flow cytometry. The percentage of positive cells was determined for each lymphocyte-related differentiation antigen. The percentages of CD3+, CD19+, and CD16+ lymphocyte subpopulations among EALs were 20%, 7%, and 3%, respectively. Nearly 70% of EALs were CD3− CD19− CD56− CD16−cells. The phenotypes of peripheral blood lymphocytes (PBLs) collected simultaneously from the patient's peripheral blood were CD3+ (52%), CD19+ (20%), and CD16+ (20%).When EALs were cultured in medium without pleural effusion, T cell-related antigens, but not B cell- or natural killer (NK) cell-related antigens, were newly expressed on EALs, and this expression reached a plateau after 48 h in culture. The proportions of CD3+, CD19+, and CD16+ cells were 69%, 7%, and 3%, respectively. However, when EALs were cultured in medium with pleural effusion, increased expression of T cell-related antigens was not observed; the proportions of CD3+, CD19+, and CD16+ cells were 16%, 6%, and 1%, respectively. Neither total cell numbers nor cellular viability of EALs changed significantly after in-vitro culture, suggesting that significant proliferation or death of EALs did not occur during the culture period. Co-culture of the patient's PBLs with autologous pleural effusion for 96 h did not alter the expression of lymphocyte-related antigens on the PBLs. These results indicate that expression of T cell-related antigens, but not B cell- or NK cell-related antigens, on EALs was blocked temporarily by the malignant pleural effusion. This is the first report concerning the existence of a large quantity of unclassified lymphocytes in which the T cell-related antigens were reversibly masked in the malignant pleural effusion.</description><subject>Antigens, CD19 - metabolism</subject><subject>CD3 Complex - metabolism</subject><subject>Cholangiocarcinoma - immunology</subject><subject>Cholangiocarcinoma - therapy</subject><subject>Humans</subject><subject>Immunotherapy, Adoptive</subject><subject>In Vitro Techniques</subject><subject>Interferon-gamma - biosynthesis</subject><subject>Lymphocytes, Tumor-Infiltrating - immunology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - immunology</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Picibanil - pharmacology</subject><subject>Pleural Effusion, Malignant - immunology</subject><subject>Pleural Effusion, Malignant - therapy</subject><subject>Receptors, IgG - metabolism</subject><subject>T-Lymphocytes - immunology</subject><issn>0882-0139</issn><issn>1532-4311</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNp1kMGK2zAQhkVp6aZpj70WnXpzq5HsWD4K104Esp16bUpORmvJbBYn3pUTyr5Bobc-4j7JOiS09LCnn2G--Rk-hD4C-QKEw1eZZR5QQojPCXuFZhAw6vkM4DWaEc6pR4BFV-jdON5NEAsW0Vt0BRR8Hvl8hn4LrES5TPD3WuSVrDa4SHH8jT39-jMFRJdcnFJtsvWqiDdVco1ljjOh5DKfrvBaJXUpFE7StL6WRY7TssiwwGtRyWTa_5DVCpdJXJflaYxXhRL5UhY4TpTCsShjmReZeI_edLof7YdLzlGdJlW88lSxlLFQXsv44uCBYS33bzprwZDAEEo56yjTNISOtBGEuvMJ5aSDyBhmwIBehL4fRtaG1FDN5ujzuffeDQ9HOx6a3XZsbd_rvR2OYxNCFAThpHOOvDPYumEcne2ae7fdaffYAGlO9pvJfvPX_sR_uhQfb3bW_KMvuieAn4HtvhvcTv8cXG-ag37sB9c5vW-3Y8Ne6g7_O721uj_cttrZ5m44uv0k7IWvngGZIpsm</recordid><startdate>20020101</startdate><enddate>20020101</enddate><creator>Onishi, Hideya</creator><creator>Morisaki, Takashi</creator><creator>Kuga, Hirotaka</creator><creator>Katano, Mitsuo</creator><creator>Doi, Fukashi</creator><creator>Uchiyama, Akihiko</creator><creator>Sugitani, Atsushi</creator><creator>Wada, Junji</creator><creator>Chijiiwa, Kazuo</creator><creator>Tanaka, Masao</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020101</creationdate><title>A LARGE QUANTITY OF CD3− CD19− CD16− LYMPHOCYTES IN MALIGNANT PLEURAL EFFUSION FROM A PATIENT WITH RECURRENT CHOLANGIO CELL CARCINOMA</title><author>Onishi, Hideya ; Morisaki, Takashi ; Kuga, Hirotaka ; Katano, Mitsuo ; Doi, Fukashi ; Uchiyama, Akihiko ; Sugitani, Atsushi ; Wada, Junji ; Chijiiwa, Kazuo ; Tanaka, Masao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-1d3c84bfee1d05d02283f23a271f0c917af40280f19dd3d1d1a674479ee72d2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Antigens, CD19 - metabolism</topic><topic>CD3 Complex - metabolism</topic><topic>Cholangiocarcinoma - immunology</topic><topic>Cholangiocarcinoma - therapy</topic><topic>Humans</topic><topic>Immunotherapy, Adoptive</topic><topic>In Vitro Techniques</topic><topic>Interferon-gamma - biosynthesis</topic><topic>Lymphocytes, Tumor-Infiltrating - immunology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - immunology</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Picibanil - pharmacology</topic><topic>Pleural Effusion, Malignant - immunology</topic><topic>Pleural Effusion, Malignant - therapy</topic><topic>Receptors, IgG - metabolism</topic><topic>T-Lymphocytes - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Onishi, Hideya</creatorcontrib><creatorcontrib>Morisaki, Takashi</creatorcontrib><creatorcontrib>Kuga, Hirotaka</creatorcontrib><creatorcontrib>Katano, Mitsuo</creatorcontrib><creatorcontrib>Doi, Fukashi</creatorcontrib><creatorcontrib>Uchiyama, Akihiko</creatorcontrib><creatorcontrib>Sugitani, Atsushi</creatorcontrib><creatorcontrib>Wada, Junji</creatorcontrib><creatorcontrib>Chijiiwa, Kazuo</creatorcontrib><creatorcontrib>Tanaka, Masao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Immunological investigations</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Onishi, Hideya</au><au>Morisaki, Takashi</au><au>Kuga, Hirotaka</au><au>Katano, Mitsuo</au><au>Doi, Fukashi</au><au>Uchiyama, Akihiko</au><au>Sugitani, Atsushi</au><au>Wada, Junji</au><au>Chijiiwa, Kazuo</au><au>Tanaka, Masao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A LARGE QUANTITY OF CD3− CD19− CD16− LYMPHOCYTES IN MALIGNANT PLEURAL EFFUSION FROM A PATIENT WITH RECURRENT CHOLANGIO CELL CARCINOMA</atitle><jtitle>Immunological investigations</jtitle><addtitle>Immunol Invest</addtitle><date>2002-01-01</date><risdate>2002</risdate><volume>31</volume><issue>2</issue><spage>121</spage><epage>135</epage><pages>121-135</pages><issn>0882-0139</issn><eissn>1532-4311</eissn><abstract>Tumor infiltrating lymphocytes (TILs) are candidates for adoptive cellular immunotherapy. Here we report on a patient whose TILs presented unusual lymphocyte antigens. Pleural effusions were collected from a 47-year-old man with recurrent cholangio cell carcinoma and malignant effusion. Effusion- associated lymphocytes (EALs) were separated by Ficoll-Hypaque gradient, and the EAL phenotype was determined by flow cytometry. The percentage of positive cells was determined for each lymphocyte-related differentiation antigen. The percentages of CD3+, CD19+, and CD16+ lymphocyte subpopulations among EALs were 20%, 7%, and 3%, respectively. Nearly 70% of EALs were CD3− CD19− CD56− CD16−cells. The phenotypes of peripheral blood lymphocytes (PBLs) collected simultaneously from the patient's peripheral blood were CD3+ (52%), CD19+ (20%), and CD16+ (20%).When EALs were cultured in medium without pleural effusion, T cell-related antigens, but not B cell- or natural killer (NK) cell-related antigens, were newly expressed on EALs, and this expression reached a plateau after 48 h in culture. The proportions of CD3+, CD19+, and CD16+ cells were 69%, 7%, and 3%, respectively. However, when EALs were cultured in medium with pleural effusion, increased expression of T cell-related antigens was not observed; the proportions of CD3+, CD19+, and CD16+ cells were 16%, 6%, and 1%, respectively. Neither total cell numbers nor cellular viability of EALs changed significantly after in-vitro culture, suggesting that significant proliferation or death of EALs did not occur during the culture period. Co-culture of the patient's PBLs with autologous pleural effusion for 96 h did not alter the expression of lymphocyte-related antigens on the PBLs. These results indicate that expression of T cell-related antigens, but not B cell- or NK cell-related antigens, on EALs was blocked temporarily by the malignant pleural effusion. This is the first report concerning the existence of a large quantity of unclassified lymphocytes in which the T cell-related antigens were reversibly masked in the malignant pleural effusion.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>12148948</pmid><doi>10.1081/IMM-120004803</doi><tpages>15</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0882-0139
ispartof Immunological investigations, 2002-01, Vol.31 (2), p.121-135
issn 0882-0139
1532-4311
language eng
recordid cdi_pubmed_primary_12148948
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects Antigens, CD19 - metabolism
CD3 Complex - metabolism
Cholangiocarcinoma - immunology
Cholangiocarcinoma - therapy
Humans
Immunotherapy, Adoptive
In Vitro Techniques
Interferon-gamma - biosynthesis
Lymphocytes, Tumor-Infiltrating - immunology
Male
Middle Aged
Neoplasm Recurrence, Local - immunology
Neoplasm Recurrence, Local - therapy
Picibanil - pharmacology
Pleural Effusion, Malignant - immunology
Pleural Effusion, Malignant - therapy
Receptors, IgG - metabolism
T-Lymphocytes - immunology
title A LARGE QUANTITY OF CD3− CD19− CD16− LYMPHOCYTES IN MALIGNANT PLEURAL EFFUSION FROM A PATIENT WITH RECURRENT CHOLANGIO CELL CARCINOMA
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T12%3A22%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20LARGE%20QUANTITY%20OF%20CD3%E2%88%92%20CD19%E2%88%92%20CD16%E2%88%92%20LYMPHOCYTES%20IN%20MALIGNANT%20PLEURAL%20EFFUSION%20FROM%20A%20PATIENT%20WITH%20RECURRENT%20CHOLANGIO%20CELL%20CARCINOMA&rft.jtitle=Immunological%20investigations&rft.au=Onishi,%20Hideya&rft.date=2002-01-01&rft.volume=31&rft.issue=2&rft.spage=121&rft.epage=135&rft.pages=121-135&rft.issn=0882-0139&rft.eissn=1532-4311&rft_id=info:doi/10.1081/IMM-120004803&rft_dat=%3Cproquest_pubme%3E71955780%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c386t-1d3c84bfee1d05d02283f23a271f0c917af40280f19dd3d1d1a674479ee72d2a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71955780&rft_id=info:pmid/12148948&rfr_iscdi=true